Skip to main content
3021 search results for:

DPP-4-Inhibitor 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-05-2024 | News

    DPP-4 inhibitors increase risk of gall bladder and bile duct disease

  2. 01-06-2024 | SARS-CoV-2 | ReviewPaper

    Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review

    Coronavirus disease 2019 (COVID-19) is still causing hospitalization and death, and vaccination appears to become less effective with each emerging variant. Spike, non-spike, and other possible unrecognized mutations have reduced the efficacy of …

  3. Open Access 18-03-2024 | Liraglutide | OriginalPaper

    Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study

    The American Diabetes Association (ADA) guideline for diabetes has set a target serum hemoglobin A1c (HbA1c) value of below 7% (52 mmol/mol) [ 1 ] based on past reports of a decrease in the incidence of microvascular complications with intensive …

  4. 01-03-2024 | Alogliptin | News

    DPP-4 inhibitor-related pemphigoid

  5. Open Access 19-12-2023 | Fatty Liver | OriginalPaper

    Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus

    The clinical implications of a novel concept named “metabolic dysfunction-associated fatty liver disease” (MAFLD) intrigue clinical interest. FLD is becoming more common and a serious public health concern. A global panel of experts proposed the …

  6. 13-04-2024 | Type 2 Diabetes | Online First

    Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study

    In Japan, dipeptidyl peptidase-4 inhibitors (DPP-4i) are widely prescribed for patients with type 2 diabetes [ 1 – 4 ] and are available in three different regimens for dosing frequency: once-daily (QD), twice-daily (BID), and once-weekly (QW). The …

  7. Open Access 05-04-2024 | Empagliflozin | BriefCommunication

    Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial

    The increasing occurrence of childhood overweight and obesity has been followed by a substantial increase in youth-onset type 2 diabetes (T2D). Pharmacological treatment options for youth-onset T2D remain limited, with a clear unmet need for …

  8. Open Access 20-03-2024 | Semaglutide | OriginalPaper

    Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a drug class that encompass multiple treatments that mimic the glucoregulatory effects of endogenous GLP-1, to reduce glycated hemoglobin (HbA 1c ) and body weight, as well as benefit people …

  9. 01-01-2024 | Vildagliptin | News

    DPP-4 inhibitor-related intestinal obstruction

  10. 03-04-2024 | Type 2 Diabetes | Online First

    Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data

    Racial differences in the pathogenesis of type 2 diabetes (T2D) are known to include the degree of insulin resistance and impaired insulin secretion [ 1 ]. In particular, insulin secretion capacity tends to be lower among Asians than in Europeans …

  11. Open Access 07-12-2023 | Semaglutide | OriginalPaper

    Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP–4i) in US Adults with Type 2 Diabetes

    This article is published with digital features, including an infographic, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.24476476 .

  12. Open Access 01-12-2023 | Stroke | OriginalPaper

    Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction

    The epidemiological trends for the incidence and prevalence of type 2 diabetes (T2D), heart failure (HF), and their co-occurrence have continued to worsen in the US and globally [ 1 ]. Diabetes is present in nearly half of HF patients, and the …

  13. 08-09-2023 | Hypoglycemia | OriginalPaper

    The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?

    During the last decade, the landscape of type 2 diabetes (T2D) management has been completely transformed, moving from a glucose-centric perspective to a holistic approach that also takes into account weight control and organ protection.

  14. Open Access 19-07-2023 | Diabetes | OriginalPaper

    Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study)

    Dipeptidyl peptidase-4 inhibitor (DPP4i) is a class of oral hypotensive agent (OHA) that carries a relatively low risk of hypoglycemia [ 1 , 2 ]. Since DPP4is are more effective, especially in the East Asian population [ 3 ], they have become the …

  15. 01-01-2023 | Acute Kidney Injury | News

    DPP-4 inhibitors have differing AE trends

  16. Open Access 01-07-2023 | Dapagliflozin | OriginalPaper

    Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

    The population of western countries is progressively aging. As the prevalence of diabetes increases with age, a large proportion of people with diabetes falls into elderly categories, often > 70 years old [ 1 ]. Treatment of diabetes in such …

  17. Open Access 01-12-2023 | Metformin | Erratum

    Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus

  18. Open Access 01-12-2023 | Diabetes | OriginalPaper

    Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus

    Diabetes mellitus (DM) is the main risk factor for the onset of atherosclerotic cardiovascular disease (ASCVD). Conversely, cardiovascular disease is the leading cause of mortality in patients with DM [ 1 ]. Moreover, patients with DM are known to …

  19. 01-07-2022 | Cholecystitis | News

    DPP-4 inhibitors increase risk of cholecystitis

  20. Open Access 01-12-2022 | Myocardial Infarction | OriginalPaper

    The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs

    Diabetes has reached alarming levels. More than half a billion people are living with diabetes worldwide and it is estimated that by 2045 there will be 693 million people diagnosed with the condition [ 1 ]. In addition, 541 million people are …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.